A compounding pharmacy that adds a controlled substance to its formulary takes on a second, federal layer of registration on top of the state license and the FDA rules that already govern 503A/503B compounding. Under 21 CFR 1301.11, every pharmacy that manufactures, dispenses, or otherwise handles a controlled substance must hold a valid DEA registration for that activity, and the registration, recordkeeping, and inventory obligations that come with it run on a separate track from the FDA's compounding oversight. A gap in either track, the DEA registration or the FDA compounding designation, exposes the pharmacy to two regulators at once.
When DEA Registration Applies to Compounding
The Controlled Substances Act defines manufacture broadly, and compounding falls inside that definition unless a specific exclusion applies. Under 21 U.S.C. 802(15), the term manufacture does not include the preparation or compounding of a drug by a practitioner, which includes a pharmacy, as an incident to dispensing that drug in the course of professional practice and in conformity with state law. That exclusion is what lets a compounding pharmacy operate under a dispenser registration rather than a manufacturer registration. It depends on two facts: the compounding is tied to a specific, valid prescription, and the pharmacy's compounding practice conforms to state pharmacy law. A pharmacy that compounds ahead of demand, in bulk, or without patient-specific orders is operating outside that exclusion.
The 503A/503B Line and Dual Exposure
The FDA's 503A/503B distinction tracks closely with the DEA's manufacture exclusion. A 503A pharmacy compounds against patient-specific prescriptions, the same condition the DEA exclusion requires, so it typically registers as a dispenser. A 503B outsourcing facility compounds in batches for office use without patient-specific prescriptions, subject to current good manufacturing practice (cGMP) requirements and FDA outsourcing-facility registration, and that same batch production puts it outside the DEA's practitioner exclusion. An outsourcing facility that handles controlled substances generally has to register with DEA as a manufacturer, not a dispenser, with the security and recordkeeping obligations that come with that category. A pharmacy that grows from patient-specific compounding into batch production without changing its DEA registration category is exposed on both the FDA and DEA sides at once.
Registration Is Tied to a Specific Location
DEA registration attaches to a specific address, not to the pharmacy's corporate license as a whole. Under 21 CFR 1301.12, a separate registration is required for each principal place of business where controlled substances are dispensed or compounded, so a pharmacy that opens a second compounding location, adds a satellite lab, or relocates its USP 797/800 sterile compounding suite needs a registration tied to that address before controlled substances arrive on-site. Registrations are not permanent. Under 21 CFR 1301.13, a retail pharmacy's DEA registration expires 36 months after issuance and must be renewed on that cycle. An expired registration functions as no registration at all for compliance purposes.
Recordkeeping and Inventory Obligations
Registration is only the entry point. Under 21 CFR 1304.04, records for Schedule I and II controlled substances must be maintained separately from other pharmacy records, while Schedule III, IV, and V records may be kept separately or integrated into ordinary business records as long as the required information is readily retrievable. Under 21 CFR 1304.11, every registrant must inventory all controlled substances on hand at least once every two years, and the compounding logs, batch records, and beyond-use date documentation the pharmacy keeps for FDA purposes do not substitute for the DEA's inventory and dispensing records. All controlled substance records must be retained for two years from the transaction date. State board of pharmacy inspections often surface these same gaps first, a separate process covered in State Board Compounding Inspections: Preparation and Response.
A DEA registration written for patient-specific dispensing does not cover a compounding pharmacy that has quietly grown into batch production.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel before expanding into controlled substance compounding, and immediately upon receiving a DEA inspection notice, an order to show cause, or an FDA Form 483. Early legal intervention can assess whether a pharmacy's compounding volume still fits the practitioner exclusion, correct a registration category before an inspector flags it, structure the recordkeeping the DEA requires apart from FDA compounding logs, and preserve the defenses available if DEA and FDA open a joint inquiry. Delaying a registration review until after an inspection notice arrives narrows the options considerably.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies on the overlap between FDA compounding rules and DEA controlled substance registration, including registration and category decisions, DEA inspections, orders to show cause, and parallel FDA enforcement, as part of the firm's compounding pharmacy defense practice. The firm reviews a pharmacy's compounding volume and prescription patterns against the practitioner exclusion, corrects registration and recordkeeping gaps before they become inspection findings, and defends pharmacies once DEA or FDA action has started. If your pharmacy is compounding controlled substances or considering it, contact us for a free, confidential consultation.
